Skip To Main Content
Forest Ray on Muck Rack

Forest Ray

Verified
Long Beach, Los Angeles
As seen in: BioNews Services, Multiple Sclerosis News Today, Wiley Online Library, National Geographic, PLOS Biology, Crain's Chicago Business, AllEvents, Pinkbike, The Ecologist, RealClear Science, GenomeWeb, Earth Island Journal and

Get in touch with Forest

Contact Forest, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Forest Ray’s Biography

Read Full Bio →

Science and sometimes investigative journalist, covering the intersections of science, ecology and everyday life.

Forest Ray’s Journalist Portfolio

See all →
Can the Ghost Dolphin Survive Obscurity? | Hakai Magazine

Can the Ghost Dolphin Survive Obscurity? | Hakai Magazine

A ghost haunts the coasts of southern Brazil, Uruguay, and northern Argentina. The franciscana, cousin to the…

View article →
Green Infrastructure: Creating Sustainable Electricity

Green Infrastructure: Creating Sustainable Electricity

Issues of rising demands on electricity and its strain on the planet's natural resources are a global problem…

View article →
Colombian Soldiers Lead Ecological Mission in High-Altitude Wetlands

Colombian Soldiers Lead Ecological Mission in High-Altitude Wetlands

Innovative army program aims to restore country's war-torn landscapes, safeguard drinking water supply Camouf…

View article →
Ecologist Special Report: Colombian Coffee Growers Adapt to a Changing Climate

Ecologist Special Report: Colombian Coffee Growers Adapt to a Changing Climate

Although petroleum is easily Colombia's biggest export, the one more associated with Colombia is coffee. Coff…

View article →
Securing a Future With Water Along Peru's Rimac River Valley

Securing a Future With Water Along Peru's Rimac River Valley

Along the Rimac River Valley of Peru, local farmers have taken the problem of water security into their own h…

View article →
Ovillantas - used tyres make a new and affordable mosquito trap in rural Mexico

Ovillantas - used tyres make a new and affordable mosquito trap in rural Mexico

The Mexican Government spends millions trying to stop the spread of mosquito-borne viruses like dengue, chiku…

View article →

Articles

Tempus AI Q2 Revenue Boost Driven by Growth in Oncology Testing With Long-Term Potential

|
By Forest Ray Verified
| GenomeWeb Verified
NEW YORK – Tempus AI saw growth in its oncology business provide significant lift to second-quarter revenues and expects growth to continue for at least the next few years, the firm said on Thursday. Meanwhile, its oncology testing products have been gaining regulatory approval and its minimal residual disease business is benefitting from its recent deal to acquire Personalis.
Open in Who Shared View Duplicates (4) Issue with article?

Personalized ASOs Reduce Seizures in Rare Epileptic Disorder, Enable One Patient to Walk Independently Original

|
By Forest Ray Verified
| Precision Medicine Online Verified
NEW YORK – A University of California, San Diego-led team has developed personalized antisense oligonucleotides (ASOs) to treat two patients with rare SCN2A-related developmental and epileptic encephalopathies, reducing the frequency of their seizures and enabling one patient to walk independently. The UCSD-led team designed individualized ASOs for two boys, each of whom inherited a disease-associated variant in the SCN2A gene, as they reported in Nature Medicine Tuesday.
Open in Who Shared View Duplicates (2) Issue with article?

One Year After IPO, Caris Life Sciences Charts Future on Potential of MCED, MRD Test Portfolio

|
By Forest Ray Verified
| GenomeWeb Verified
NEW YORK – One year on since Caris Life Sciences went public, the company has launched several new products, including a multi-cancer early detection assay, obtained a series of regulatory approvals, and advanced its artificial intelligence capabilities, all while weathering gyrations in its stock price. And despite some bumps along the way, Caris President David Spetzler said that the firm remains on target with its cancer testing portfolio and is upbeat about its path moving forward.
Open in Who Shared View Duplicates (2) Issue with article?
See all 1,585 licensed articles (1,586 Total)